Shareholding disclosure

Sofinnova Capital IV FCPR

Declared position

4.26%

Threshold

Crossed upwards

Timeline

Published

20.02.2014

Transaction

11.02.2014

Voting rights breakdown

Voting rights acquired4.26%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAE2I00031

Beneficial owner

Sofinnova Capital IV FCPR

Declared address

SOFINNOVA CAPITAL IV FCPR, 75008 PARIS

5% threshold of purchase positions crossed down further to sale.

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Sofinnova Capital IV FCPR

Addex Therapeutics Ltd20.02.2014TAE2I00031

Disclosure summary

Sofinnova Capital IV FCPR disclosed a holding in Addex Therapeutics Ltd on the acquisition side, published by SIX Exchange Regulation on 20.02.2014, at 4.26% of voting rights. Notice category: Single shareholder.

Disclosed position

4.26%

Voting rights acquired

Voting rights acquired4.26%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Sofinnova Capital IV FCPR disclosed a holding in Addex Therapeutics Ltd, published on 20.02.2014.

Publication date20.02.2014

Transaction date11.02.2014

Issuing companyAddex Therapeutics Ltd

Beneficial ownerSofinnova Capital IV FCPR

Declared addressSOFINNOVA CAPITAL IV FCPR, 75008 PARIS

CategorySingle shareholder

Voting rights acquired4.26%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAE2I00031

Conditions

5% threshold of purchase positions crossed down further to sale.

Source: SIX Exchange Regulation · Publication date: 20.02.2014

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open